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REPORT
Common Single-Nucleotide Polymorphisms Act in Concert
to Affect Plasma Levels of High-Density Lipoprotein Cholesterol
Victor Spirin,* Steffen Schmidt,* Alexander Pertsemlidis, Richard S. Cooper, Jonathan C. Cohen,
and Shamil R. Sunyaev
The identification of DNA sequence variants underlying human complex phenotypes remains a significant challenge for
several reasons: individual variants can have small phenotypic effects or low population frequencies, and multiple allelic
variants may act in concert to affect a trait. We evaluated the combined effect of allelic variants in seven genes involved
in high-density lipoprotein (HDL) metabolism, using forward stepwise regression. Analysis of all known common single-
nucleotide polymorphisms (SNPs) in the seven candidate genes revealed four variants that were associated with incre-
mental changes in HDL cholesterol levels in three independent samples. Conversely, analysis of 660 polymorphisms in
eight genes that do not appear to be involved in HDL metabolism did not identify any associations with plasma HDL-
cholesterol levels. These data indicate that several common SNPs act in concert to influence plasma levels of HDL
cholesterol.
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The plasma level of high-density lipoprotein cholesterol
(HDL-C) provides a useful model system for analysis of
the genetic architecture of complex traits: several genes
involved in HDL metabolism have been well characterized
biochemically,1 and several Mendelian disorders of HDL
metabolism have been elucidated.2 Multiple rare variants
in three genes responsible for Mendelian forms of low
HDL (ABCA1 [MIM 600046], APOA1 [MIM 107680], and
LCAT [MIM 606967]) collectively contribute to variation
in plasma HDL levels in the population,3,4 but such vari-
ants were identified in a minority of individuals (∼15%)
with low HDL levels. In this study, we examined the con-
tribution of common sequence polymorphisms to varia-
tion in HDL-C levels. Several studies have reported that
common sequence variants are associated with plasma lev-
els of HDL-C, but the individual effects of these alleles are
small.5 Earlier work on model organisms provides exam-
ples of additive contribution of multiple genetic variants
of small individual effects to quantitative trait variation.6
Accordingly, we evaluated the hypothesis that HDL-C lev-
els reflect the cumulative contributions of multiple com-
mon DNA sequence variants, each of which has a small
effect.
We focused on all known, common SNPs in seven key
genes that mediate HDL metabolism (APOA1, ABCA1, CETP
[MIM 118470], LPL [MIM 609708], PLTP [MIM 172425],
LIPC [MIM 151670], and LIPG [MIM 603684]). A total of
797 SNPs in these genes were identified through dbSNP
and were genotyped in 3,306 participants in the Dallas
Heart Study (DHS),7 a population-based probability sam-
ple of African American, European American, and His-
panic men and women. Before the analysis, we randomly
divided the DHS population into two groups. The first set
of 1,700 individuals (the training set) was used to develop
the statistical model, and the second set of all the re-
maining individuals (the testing set) was used to test and
validate the model. After elimination of poor genotypes
and duplicates, the training set was reduced to 1,580 in-
dividuals, and the testing set comprised 1,726 individuals.
A parallel analysis was also performed on the entire DHS
population.
To take into account stratification of the DHS popula-
tion according to race and sex, we used the analysis of
covariance (ANCOVA), which allows for differences in
HDL-C levels among population groups, while aiming at
identification of alleles with the same effect within groups.
HDL-C levels were log-transformed to better approximate
a normal distribution. Stepwise regression was used to
build a linear model incorporating sex, race, and multiple
genetic factors. The initial “seed” model considered only
the effects of sex and ethnicity. Each of the 797 SNPs was
then added to the model, and the SNP that provided the
greatest increase in likelihood was identified. If the in-
crease in likelihood was significant (as determined by a
permutation test), then the SNP was incorporated into the
model. If the P value of any of the previously added SNPs
became insignificant, that SNP was removed from the mod-
el. The process was repeated using the remaining SNPs. At
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Table 1. ANCOVA P Values for the Model and Individual SNPs for All Data Sets
SNP(s)
P by Set
Standardized
Regression
CoefficientTraining Test Validation DHS DHS-Maywood
CETP rs183130 1.34#106 4.04#104 8.00#104 5.18#109 7.46#1011 1.50
CETP rs5880 8.16#106 9.55#105 5.95#103 1.19#108 6.86#1010 1.27
LPL rs326 1.27#102 3.07#104 1.98#102 2.17#105 9.14#107 1.15
PLTP rs3843763 3.85#102 7.07#103 2.86#102 1.00#103 1.51#104 .86
Modela 2.30#1014 4.83#1011 3.28#107 8.01#1024 3.67#1029 …
NOTE.—A one-sided test was used for the validation set, and two-sided tests were used for other data sets.
Standardized regression coefficients are shown for HDL-C levels without logarithmic transformation and for the
combined set only.
a Includes all four SNPs.
Table 2. HDL-Lowering SNPs
SNP
Nucleotide
Change
Allele Minor-Allele Frequency
Ancestral Minor
HDL
Lowering
Non-Hispanic
White
Non-Hispanic
Black Hispanic
CETP rs183130 C/T T T C .325 .246 .322
CETP rs5880 C/G G C C .063 .012 .117
LPL rs326 A/G G G A .289 .558 .250
PLTP rs3843763 C/T C T T .270 .165 .356
each step, the model considered only individuals with
available genotype information for all selected SNPs. The
procedure was terminated when the addition of new SNPs
no longer significantly improved the model likelihood,
with use of a P value threshold of 103. Simulation studies
indicated that, at this threshold, the model would pick
about one-half of a false-positive SNP, on average, in the
training set, whereas the chance of successful validation
for the testing set at the significance level of 103 is ∼1 in
1,000. The model is purely additive and does not incor-
porate dominance or epistatic interactions. Importantly,
the stepwise regression strategy takes into account depen-
dence of SNPs due to linkage disequilibrium (LD). The
model will select a minimal combination of SNPs and will
not include multiple redundant SNPs in LD. However, the
model will include multiple SNPs in LD if all of them are
functional. Although the power to add more SNPs to the
model is reduced when there is strong LD, this effect is of
limited magnitude (table C1). Computer simulations sug-
gest that, at least for additive effects, stepwise regression
has higher power to detect multiple functional SNPs in
LD than does analysis of variance (ANOVA) of haplotype
effects (table C2).
In the training set, the first two iterations resulted in
the addition of two CETP SNPs (rs183130 [Pp 9.62#
] and rs5880 [ ]) to the model. The third8 610 Pp 1.90#10
and fourth iterations added SNPs from PLTP (rs6065904
[ ]) and LPL (rs2197089 [ ]).4 4Pp 5.88# 10 Pp 8.02# 10
All SNPs remained significant after the addition of the
subsequent SNPs. To account for possible deviations from
normality, we also used permutation tests to confirm that
addition of each of the SNPs increased the significance of
the model. The P value for the model containing all four
SNPs was , when the effect of race and sex183.06# 10
was not considered. The same model was obtained when
individuals with plasma triglyceride levels 250 mg/dl,
which are strongly associated with low plasma levels of
HDL-C,8 were excluded from the analysis. The model was
then evaluated in the testing set. As in the training set,
the P value for the combined model was highly significant
( , one-sided test). This model is not driven7Pp 3.14# 10
solely by CETP variants and remains nominally significant
for the testing set if CETP is excluded from the analysis.
To optimize the model, we reanalyzed all SNPs that were
in strong LD ( in all populations) with the four′D 1 0.9
SNPs originally included in the model in the training set.
Using SNPs from these LD blocks, we selected the model
with the lowest P value in the testing set. The final model
was highly significant in both training and testing sets,
with and (one-sided14 11Pp 2.30# 10 Pp 4.83# 10
test), respectively. The individual contributions of each of
these four SNPs to the model were statistically significant
in both the training and the testing data sets (table 1).
Although partitioning the DHS population into two
groups allows training and testing steps to be performed
with independent data sets, analysis of the entire sample
would provide greater power to detect SNPs associated
with HDL-C.9 Thus, we repeated the forward stepwise re-
gression for the complete DHS population (table 1). The
same four SNPs were included in the model, and no ad-
ditional SNPs were selected.
To validate the model, we assayed the four SNPs in an
independent population of 849 African American men
and women from Maywood (suburban Chicago). All four
SNPs were significantly associated with HDL-C levels (ta-
ble 1), and their combined effect was highly significant
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Figure 1. Dependence of HDL-C levels on the total number of HDL-lowering alleles of the four SNPs included in the model. The figure
shows HDL-C levels rather than the logarithmic HDL-C levels used in the analysis. For illustration, we show the number of derived alleles
without regression coefficients of the corresponding SNPs. A, Training set. B, Testing set. C, Validation set.
( , one-sided test). Because the Maywood7Pp 3.28# 10
sample includes only individuals of African American de-
scent, race was not considered a parameter of the model
in this population. Similar results were obtained when the
model was tested with the merged DHS-Maywood data set
(table 1).
The number of HDL-lowering alleles was strongly cor-
related with plasma HDL-C levels. Of the DHS population,
∼10% has two or fewer HDL-lowering alleles, and ∼10%
has six or more. The mean weighted HDL-C levels in the
training set were, respectively, 55.2 mg/dl and 44.1 mg/
dl for individuals in these groups (fig. 1A). In the testing
set, the HDL-lowering alleles reduced the average plasma
HDL-C level in the corresponding groups from 52.6 mg/
dl to 44.8 mg/dl (fig. 1B), and, in the Maywood popula-
tion, from 55.8 mg/dl to 47.3 mg/dl (fig. 1C). However,
our analysis of all common SNPs in the reverse cholesterol
pathway was able to explain only 2.2% of variance of HDL-
C level in the DHS population. Standardized regression
coefficients for the four SNPs are shown in table 1.
Three of the sequence variants in the model are very
common, noncoding SNPs with minor-allele frequencies
125% (table 2). The fourth SNP (CETP A390P [rs5880]) is
less common (minor-allele frequency 4.6%) and is the
only nonsynonymous SNP that was significantly and re-
producibly associated with HDL-C. The two CETP variants
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Table 3. ANCOVA P Values for the Model That
Incorporates Race, Sex, Age, and BMI
SNP
P by Set
DHS DHS-Maywood
CETP rs183130 5.49#1010 4.73#1012
CETP rs5880 1.71#108 7.48#1010
LPL rs326 1.30#106 3.49#108
HUPLTP rs3843763 4.37#104 1.19#104
Modela 2.99#1026 6.29#1032
a Includes all four SNPs.
are not in strong LD with each other ( for′D p 0.462
whites, for blacks, and for His-′ ′D p 0.0073 D p 0.642
panics). One of the two CETP SNPs (rs183130) is in strong
LD with a TaqI SNP (rs708272) that was associated with
HDL-C levels earlier.10
We further considered the effect of additional nonge-
netic variables: BMI and age. BMI was strongly correlated
with HDL-C level, and age showed a weak though signif-
icant correlation with HDL-C in the DHS population. The
effect of the four SNPs on HDL-C remains significant in
a model that includes race, sex, age, and BMI (table 3).
To test for epistatic interactions among the four allelic
variants, we introduced pairwise interaction terms in the
linear model. These terms would account for the contri-
bution of pairs of interacting SNPs to plasma HDL-C level
beyond a simple additive effect. All pairwise interactions
between SNPs in our model appeared to be insignificant.
Thus, we did not identify any epistatic interactions. How-
ever, two SNPs (CETP rs183130 and LPL rs326) had nom-
inally significant interactions with BMI ( andPp .033
, respectively).Pp .031
We attempted to include additional SNPs in the model
by relaxing the threshold for inclusion. In every case, how-
ever, the SNPs that were added in the training set nega-
tively affected performance of the model for the testing
and validation sets. Also, the additional SNPs did not have
consistent individual effects on HDL-C levels in the train-
ing and testing sets. Our study certainly does not exclude
the possibility that other allelic variants with small effects
on HDL-C were not included in our model because of
insufficient power. For example, a SNP in the hepatic li-
pase gene (514CrT) that contributed to variation in
HDL-C levels in other populations11,12 was associated with
modest increases in HDL-C in all three data sets in our
study but was not selected by the model at our conser-
vative threshold.
For a negative control, we analyzed 660 SNPs from eight
genes that do not appear to play a significant role in HDL
metabolism—AACS, ABCG5 (MIM 605459), ABCG8 (MIM
605460), ACACA (MIM 200350), CART (MIM 602606),
GHRL (MIM 605353), MC3R (MIM 155540), and SIM1
(MIM 603128). These SNPs were analyzed using the AN-
COVA procedure described above. No SNP was added to
the model at a significance threshold .001. Although one
SNP had a P value close to this threshold on the training
set, this SNP together with all SNPs in LD with it were not
significant in either the training or the testing set indi-
vidually. We then relaxed the threshold so at least three
SNPs were included in the model. The resulting model
and individual SNPs were not significant in the testing set.
This study suggests that the combined effect of fre-
quent SNPs of small individual effects can be important
in the inheritance of complex phenotypes. The observa-
tion that multiple SNPs have an effect on HDL-C level,
including rare SNPs with large effects and frequent SNPs
of smaller effects, is consistent with an evolutionary
model of purifying selection. The action of purifying se-
lection would keep allelic variants of larger effect at low
frequency while allowing smaller-effect variants to reach
higher frequencies.
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Appendix A
Population Study Subjects
The African American sample was recruited from May-
wood, IL, a working-class community near Chicago, ∼10
miles from downtown. The survey enrolled a represen-
tative random sample of the population, aged 18–74 years.
The study population included all participants in the
DHS from whom fasting venous blood samples were ob-
tained ( ). The DHS is a multiethnic probability-np 3,543
based sample of Dallas County (Texas) weighted to include
50% African Americans subjects, as described elsewhere.7
The blood samples were maintained at 4C until the plas-
ma and serum were separated, aliquoted, and stored at
80C. Genomic DNA was isolated from the leukocytes
with use of Pure Gene (Gentra Systems).
Measurement of Plasma HDL-C Levels
Plasma HDL-C concentrations were determined using
commercial enzymatic reagents, as described elsewhere.13
Assay of Mutations
DHS SNPs were assayed by PCR-based amplification of
genomic DNA, followed by hybridization to high-density
oligonucleotide arrays (Perlegen Sciences). The four SNPs
analyzed in the Maywood samples were assayed by real-
time PCR.
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Table C2. Power of Regression versus
ANOVA Analysis of Haplotype Effects
Analysis
Power by D’
.0 .25 .5 .75 .9 1.0
Regression .76 .82 .87 .91 .94 .93
Haplotype .51 .58 .66 .71 .78 .86
NOTE.—With SNP minor-allele frequencies .15 and
.3, coefficients .5, and SD 15.
Table C1. Power to Include the
Second Functional SNP in the Model,
as a Function of LD between Two
Functional SNPs
SNP
Power by D’
.0 .25 .5 .75 .9 1.0
1a .45 .47 .44 .36 .33 .30
2b .94 .95 .89 .82 .69 .61
NOTE.—The table represents a subset of a
broader range of parameters.
a With minor-allele frequencies .15 and .3,
coefficients .5, and SD 15.
b With minor-allele frequencies .3 and .4, co-
efficients .75, and SD 15.
Appendix B
Stepwise Regression
This procedure involves (1) identification of a “seed”
model, (2) iterative alteration of the model by addition of
a SNP in accordance with the P value criteria, (3) backward
elimination—that is, removal of previously added SNPs if
their P values are no longer significant, and (4) termina-
tion of the search when addition no longer significantly
improves the likelihood of the model.
The seed model is an ANCOVA linear model that incor-
porates race and sex only. The first iteration attempts to
add a SNP to this model. The log-likelihood change as a
result of this addition obeys a x2 distribution with 1 df.
To choose the best candidate for the addition to the
model, all SNPs are ranked by the P value of the corre-
sponding log-likelihood change. The highest-ranked SNP
is added to the model if its P value is significant. To take
into account possible deviation from normality, we also
test whether the addition of a SNP to the model is sig-
nificant according to the permutation test. The next it-
eration attempts to add the next SNP to the model. SNPs
are ranked again according to log-likelihood P values. The
highest-ranked SNP is added to the model on the basis of
the same criteria. If the P value of any of the previously
added SNPs is not significant, that SNP is eliminated, al-
though no elimination step was necessary in our study.
The process stops when the addition of a SNP does not
significantly improve the model.
Appendix C
Power to Include Multiple Functional SNPs in LD
The stepwise regression strategy does not incorporate
multiple redundant SNPs in LD into the model. At the
same time, it is expected to incorporate all functional SNPs,
even if they are in LD. Strong LD, however, reduces power
to incorporate multiple functional SNPs. We attempted to
quantify this reduction of power via simulation. We sim-
ulated 1,000 individuals with two functional SNPs in LD
that had a given D′. A quantitative phenotype was mod-
eled as the sum of the effects of two SNPs and Gaussian
noise. We simulated a range of D′ values, allele frequencies,
and effect sizes but assumed no epistatic interactions. We
estimated power as the probability that both SNPs will be
included in the model by stepwise regression and that the
increase of the likelihood due to the inclusion of the sec-
ond SNP will be significant at the level of . As seenPp .05
in table C1, the power to add the second SNP to the model
indeed decreases, although the decrease is limited.
Efficiency of Haplotype Analysis
We also tested whether an alternative strategy of ANOVA
of all haplotypes is more efficient for detecting multiple
functional SNPs in LD. We found that, in this simple case,
the regression model has higher power to reject the hy-
pothesis that the phenotype is independent of SNPs than
does the ANOVA model for haplotypes (table C2).
Also, the chance that the second SNP will be added to
the regression model by stepwise regression is higher than
the chance that the haplotype of the largest effect will be
identified by ANOVA as the most significant (that it will
achieve the nominal significance level and will have a P
value lower than any other haplotype). Even for ′D p
in the case of SNP allele frequencies 0.15 and 0.3 and1.0
strength of the effect of 0.5 for each SNP, stepwise re-
gression has a 30% chance to add the second SNP to the
model, whereas the haplotype of two functional alleles is
detected by ANOVA as the most significant only in 22%
of cases. We admit, however, that our model is purely
additive and that a simple ANOVA test possibly is not the
most efficient way to conduct the haplotype analysis, be-
cause heterozygotes and homozygotes for the same hap-
lotype are treated as independent groups. We note, how-
ever, that applying the Cochran-Armitage test with true
effect sizes of haplotypes (unknown in practice) provided
only a small increase in power compared with the stepwise
regression model (data not shown).
Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for (ABCA1, APOA1, LCAT, CETP, LPL,
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PLTP, LIPC, LIPG, ABCG5, ABCG8, ACACA, CART, GHRL, MC3R
and SIM1)
S.R.S.’s Web site, http://genetics.bwh.harvard.edu/genetics/labs/
Sunyaev/HDL/index.html (for information about allele fre-
quencies and LD for all SNPs included in this study)
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